BR112022023031A2 - Terapia de combinação para amiloidose por ttr - Google Patents

Terapia de combinação para amiloidose por ttr

Info

Publication number
BR112022023031A2
BR112022023031A2 BR112022023031A BR112022023031A BR112022023031A2 BR 112022023031 A2 BR112022023031 A2 BR 112022023031A2 BR 112022023031 A BR112022023031 A BR 112022023031A BR 112022023031 A BR112022023031 A BR 112022023031A BR 112022023031 A2 BR112022023031 A2 BR 112022023031A2
Authority
BR
Brazil
Prior art keywords
ttr
combination therapy
amyloidosis
ttr amyloidosis
attr
Prior art date
Application number
BR112022023031A
Other languages
English (en)
Portuguese (pt)
Inventor
MICHALON Aubin
Grimm Jan
Original Assignee
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Ag filed Critical Neurimmune Ag
Publication of BR112022023031A2 publication Critical patent/BR112022023031A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112022023031A 2020-05-12 2021-05-12 Terapia de combinação para amiloidose por ttr BR112022023031A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20174177 2020-05-12
PCT/EP2021/062706 WO2021228987A1 (en) 2020-05-12 2021-05-12 Combination therapy for ttr amyloidosis

Publications (1)

Publication Number Publication Date
BR112022023031A2 true BR112022023031A2 (pt) 2022-12-20

Family

ID=70682637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023031A BR112022023031A2 (pt) 2020-05-12 2021-05-12 Terapia de combinação para amiloidose por ttr

Country Status (13)

Country Link
US (1) US20230183329A1 (https=)
EP (1) EP4149972A1 (https=)
JP (1) JP7834032B2 (https=)
KR (1) KR20230009950A (https=)
CN (1) CN115551886A (https=)
AU (1) AU2021272369A1 (https=)
BR (1) BR112022023031A2 (https=)
CA (1) CA3172824A1 (https=)
CL (2) CL2022003141A1 (https=)
CO (1) CO2022017877A2 (https=)
IL (1) IL298135A (https=)
MX (1) MX2022014223A (https=)
WO (1) WO2021228987A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023099788A1 (en) * 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
AU2023382527A1 (en) * 2022-11-15 2025-06-26 Alexion Pharmaceuticals, Inc. Methods for treating or preventing transthyretin-mediated amyloidosis
WO2024240562A1 (en) 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
WO2025104243A1 (en) 2023-11-15 2025-05-22 Neurimmune Ag Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis
WO2025238147A1 (en) * 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US10344080B2 (en) * 2013-12-20 2019-07-09 Neurimmune Holding Ag Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
EP3101131B1 (en) 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
EP3981874A1 (en) 2014-01-29 2022-04-13 KM Biologics Co., Ltd. Anti-transthyretin human antibody
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
CU24731B1 (es) * 2017-10-06 2025-01-15 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
CU20200042A7 (es) * 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
US20210400932A1 (en) 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model

Also Published As

Publication number Publication date
CL2022003141A1 (es) 2023-07-21
WO2021228987A1 (en) 2021-11-18
EP4149972A1 (en) 2023-03-22
CL2025001129A1 (es) 2025-11-28
US20230183329A1 (en) 2023-06-15
AU2021272369A1 (en) 2023-01-19
MX2022014223A (es) 2023-04-14
CO2022017877A2 (es) 2023-02-27
JP7834032B2 (ja) 2026-03-23
KR20230009950A (ko) 2023-01-17
IL298135A (en) 2023-01-01
JP2023525790A (ja) 2023-06-19
CA3172824A1 (en) 2021-11-18
CN115551886A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
BR112022023031A2 (pt) Terapia de combinação para amiloidose por ttr
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
MX2024003373A (es) Dosis de complejos dirigidos a musculos para el tratamiento de distrofinopatias.
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CO2023001561A2 (es) Combinaciones para el tratamiento de cáncer
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BRPI0513168A (pt) memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia
BR112023018745A2 (pt) Método para tratar nefropatia por iga com proteína de fusão de taci-fc
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
CL2024001870A1 (es) Paradigma de tratamiento para una terapia con anticuerpos anti-cd19.
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
BR112022026094A2 (pt) Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit
BR112022019518A2 (pt) Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo